- Business - 18:00
Supercomputing set to boost region’s competitiveness - Medicine - 18:00
’How- to’ video tutorials could boost hearing aid use, say researchers - Environmental Sciences - 14:00
Oil expertise centre to boost growth - Life Sciences - 13:00
Marine biologist works with primary school to teach children about life under the waves - Business - 13:00
Netball star to represent GB - Medicine - 12:00
Allocating NHS funds by age only would benefit affluent Conservative areas of England - History - 11:00
Ebb Tide exhibition reveals stories from the hidden depths of human history - Computer Science - 10:00
New £3.5m supercomputing investment set to boost regions competitiveness - Social Sciences - 10:00
“We need more than peace to stop the wars” - Administration - 10:00
The changing face of British intelligence - History - 10:00
Trench art features in new WW1 exhibition - Medicine - 09:00
Patients to benefit from better advice on pain control
Administration
Chemistry
Physics
Environmental Sciences
Earth Sciences
Life Sciences
Medicine
Business
Literature
History
Pedagogy
Social Sciences
» » more
£1 million drug treatment study launched
08 Dec 2011
University of Manchester researchers have been awarded £1 million to investigate the effectiveness of the Department of Health’s ‘Payment by Results’ (PbR) schemes in the treatment of addiction.
PbR was introduced by the last government to link clinical healthcare pay to performance by using patient experience and clinical outcomes; instead of being paid a set amount for a given procedure, under PbR NHS trusts are paid according to the quality of care they provide.
The Manchester team, led by Michael Donmall, a Reader in Health Sciences, and Professor Matt Sutton, Professor of Health Economics, say the research will deliver a robust assessment of this approach to the care of problem drug users, in work that has key national policy implications.
The three year study, with Manchester colleagues Tim Millar and Andrew Jones and collaborators at Birkbeck, London, RAND Europe and User Voice, will have process, impact and economic research components in eight pilot sites across England, with comparison to provision before introduction of PbR where possible and to non PbR sites where required.
Donmall, who is Director of the National Drug Evidence Centre based at Manchester, said: “The pilots will be assessed by both process and impact evaluation, including reviewing existing research, mapping existing service delivery, and describing each PbR model alongside the different approaches developed.
“There will be in-depth examination of implementation, delivery and development. Monitoring data will be analysed alongside extensive ing of PbR stakeholders. Treatment outcomes will be analysed statistically in comparison to non-PbR sites via anonymised data linkage of existing data sources.
“The economic component of the evaluation will assess: the affordability of the schemes; whether the PbR schemes represent good value for money compared to alternative arrangements; the influence on provider behaviour, and the impact on the provider market.”
Last job offers
- Law - 21.5
Doctoral Programme at the Law School of the University of Basel - Life Sciences - 19.4
Senior Expert - Genetic Biomarker Oncology (PhD) m/f - Literature - 23.5
Research Fellow (Australia) - Environmental Sciences - 23.5
Coordinator of the All Party Parliamentary Group on Food and Agriculture for Development / Policy Research... - Life Sciences - 22.5
Post-doctoral Research Fellow - Physics - 21.5
Postdoctoral Research Associate : GAIA Project - Life Sciences - 18.5
Postdoctoral Research Assistant - Physics - 18.5
Senior Research Associate



» Share this page: